歌礼制药-B在2025年肥胖周(ObesityWeek )报告 ASC30口服片 Ib期研究的完整分析、ASC30注射剂Ib期研究以及ASC31与ASC47联合用药临床前研究

Core Insights - The announcement highlights multiple reports presented at the 2025 ObesityWeek in Atlanta, Georgia, focusing on the efficacy and safety of the company's obesity treatment pipeline [1] - The reports include a complete analysis of the ASC30 oral tablet Phase Ib study, the ASC30 monthly injection Phase Ib study, and preclinical studies of ASC31 and ASC47 combination therapy [1] - The company's proprietary technologies, including AI-assisted drug discovery and ultra-long-acting drug development platforms, are emphasized as key components of their research [1] - The CEO expresses a commitment to advancing clinical development while engaging closely with strategic partners to meet global obesity treatment needs [1]